GSK makes biggest ever acquisition with $10.6bn for US cancer drug firm
GSK's Largest Acquisition: A $10.6bn Move into US Cancer Drug Market
GSK makes biggest ever acquisition with 10 - Under the leadership of its new chief executive, Luke Miels, GlaxoSmithKline (GSK) has completed its most significant acquisition in company history, acquiring Nuvalent, a Boston-based biotech firm specializing in oncology, for $10.6bn (£7.9bn). This deal marks a pivotal moment for GSK, expanding its portfolio of cancer treatments and signaling a bold shift in its strategy. The transaction involves a cash payment of $124 per share, offering Nuvalent’s shareholders a substantial return. With the acquisition, GSK aims to strengthen its position in the oncology sector, which has seen growing importance in the pharmaceutical industry over recent years.
Founding and Growth of Nuvalent
Nuvalent, a biotechnology company based in Boston, was established in 2017 by Matthew Shair, a Harvard professor renowned for his expertise in chemistry and chemical biology. The firm went public on the Nasdaq stock exchange in 2021, which provided it with the capital needed to advance its drug development pipeline. As part of the deal, Shair retains a 2.16% stake in Nuvalent, translating to an estimated $200m profit from the sale. Nuvalent’s largest shareholder is Deerfield Management, a New York-based healthcare investment firm that has supported the company’s growth trajectory. The acquisition highlights the potential for biotech startups to achieve major milestones through strategic partnerships with larger pharmaceutical companies.
Targeted Cancer Therapies and FDA Reviews
At the heart of the deal are two late-stage medications developed by Nuvalent: zidesamtinib and neladalkib. Both drugs are in the advanced phase of clinical trials for non-small cell lung cancer (NSCLC), a prevalent form of the disease. The US Food and Drug Administration (FDA) is currently evaluating these treatments, with decisions anticipated in September and November. If approved, the drugs are expected to reach the market by the end of the year, potentially becoming blockbuster products with annual revenues projected to exceed several billion dollars. These therapies are designed to provide extended treatment options for patients with specific lung cancer mutations, offering improved tolerability and a better quality of life compared to existing treatments.
Strategic Expansion and CEO’s Vision
This acquisition is the latest step in Luke Miels’ strategy to bolster GSK’s oncology capabilities. Miels, who previously served as the company’s chief commercial officer, has been leading a series of acquisitions since taking over from Emma Walmsley at the start of 2026. Prior to this, GSK had acquired the California-based biotech RAPT for $2.2bn in January, focusing on allergic disease treatments. However, the Nuvalent deal represents a more substantial leap, surprising investors after a string of smaller, targeted purchases in recent years. “We’ve been building this step by step,” Miels explained, emphasizing the “brick-by-brick approach” to growth. “The two lead products are potential best-in-class assets that could launch this year if approved by the FDA, offering transformative options for patients with two forms of NSCLC.”
According to Miels, the decision to acquire Nuvalent was made over a year ago, driven by the company’s innovative team and promising research. “Nuvalent’s scientists are an impressive group of people,” he noted, underscoring the value of the collaboration. The CEO highlighted the need for improved treatments in lung cancer, citing the challenges faced by patients currently on the market. “Many of these patients have to endure seven or eight years of treatment, often leading to weight gain and reduced quality of life,” Miels said. He pointed out that the majority of NSCLC cases in the US involve female non-smokers aged 40 to 50, a demographic that stands to benefit significantly from the new therapies.
Historical Context and Future Ambitions
GSK’s acquisition of Nuvalent surpasses its previous largest transaction, a $21bn asset swap with Novartis in 2014. In that deal, GSK took over Novartis’ vaccines division for $5.25bn and transferred its cancer portfolio to the Swiss company for $16bn. The Nuvalent acquisition, however, marks a renewed focus on oncology, aligning with Miels’ vision to drive growth in this area. “This deal is a testament to our commitment to advancing oncology innovation,” Miels added, highlighting the potential for new revenue streams. The company also aims to leverage Nuvalent’s development of Ris-Rez, a late-stage clinical candidate that could treat multiple cancer types, to meet its target of exceeding £40bn in annual sales by 2031.
The acquisition is expected to generate immediate profit contributions starting in 2027, as GSK anticipates commercial success from the new drugs. Nuvalent’s products, particularly Ris-Rez, are seen as a critical asset for the company’s long-term growth. Miels described the deal as a strategic move to “create a platform for rapid expansion” in the lung cancer space. Analysts, however, remain cautious about GSK’s ambitious sales targets. While the Nuvalent acquisition is a significant milestone, some experts argue that the current financial projections do not fully account for the complexities of scaling up production and marketing for these new therapies.
Market Reactions and Investor Implications
The announcement of the deal had a mixed impact on stock markets. Nuvalent’s shares surged by 38% in pre-market trading on Tuesday, reaching $122 per share, reflecting investor optimism about the company’s future. In contrast, GSK’s shares fell by 1.4% by early afternoon, possibly due to the large financial commitment involved. Despite the market’s initial reaction, the deal is viewed as a long-term investment in oncology innovation. “This is not just a short-term play; it’s about positioning GSK as a leader in cancer treatment,” Miels stated during a press briefing. The acquisition underscores GSK’s determination to compete in a rapidly evolving industry, where breakthrough therapies are increasingly valued.
As GSK integrates Nuvalent’s research into its existing oncology programs, the company is poised to benefit from the combined expertise and resources of both entities. The deal also reinforces the trend of large pharmaceutical firms acquiring smaller biotechs to accelerate drug development and diversify their offerings. With the addition of Nuvalent’s therapies, GSK’s oncology portfolio is expected to grow significantly, enhancing its competitive edge. However, the success of this strategy will depend on the FDA’s approval of zidesamtinib and neladalkib, as well as the market’s acceptance of these new treatments. The acquisition serves as a clear signal of GSK’s commitment to oncology, marking a new chapter in its pharmaceutical journey.
“The two lead products are potential best-in-class assets that could launch this year if approved by the FDA, offering significant new treatment options to patients with two forms of non-small cell lung cancer.”